Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: A National Cancer Institute of Canada Clinical Trials Group investigational new drug study

By Winquist Eric   Knox Jennifer   Ayoub Jean-Pierre   Wood Lori   Wainman Nancy   Reid Gregory   Pearce Laura   Shah Ajit   Eisenhauer Elizabeth  

Investigational New Drugs, Vol. 24, Iss. 2, 2006-03 ,pp. : 159-167

Springer Publishing Company

Access to resources Recommend Favorite

A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group

By Goss G.   Hirte H.   Miller W.   Lorimer I.   Stewart D.   Batist G.   Parolin D.   Hanna P.   Stafford S.   Friedmann J.   Walsh W.   Mathews S.   Douglas L.   Seymour L.  

Investigational New Drugs, Vol. 23, Iss. 2, 2005-01 ,pp. : 147-155

Springer Publishing Company

Access to resources Recommend Favorite

The US Food and Drug Administration and Emergency Contraception

By Fox Anthony W.  

International Journal of Pharmaceutical Medicine, Vol. 19, Iss. 3, 2005-01 ,pp. : 139-140

Adis International

Access to resources Recommend Favorite

Post-Launch Clinical Investigator Drug Prescribing in the US: The Behaviour of Clinical Trial Investigators after Participating in Phase III Trials

By Glass Harold E.   Rosenthal Bruce  

International Journal of Pharmaceutical Medicine, Vol. 19, Iss. 2, 2005-01 ,pp. : 97-104

Adis International

Access to resources Recommend Favorite

Drug Interactions with New and Investigational Antiretrovirals

By Brown Kevin C.   Paul Sunita   Kashuba Angela D.M.  

Clinical Pharmacokinetics, Vol. 48, Iss. 4, 2009-06 ,pp. : 211-241

Adis International

Access to resources Recommend Favorite